Standard Treatment Guidelines
... guidelines list the preferred treatments for common health problems experienced by people in the health system and were subjected to stakeholder discussions before being finalised to ensure that the opinion of the intended users were considered and incorporated. The guidelines are designed to be use ...
... guidelines list the preferred treatments for common health problems experienced by people in the health system and were subjected to stakeholder discussions before being finalised to ensure that the opinion of the intended users were considered and incorporated. The guidelines are designed to be use ...
Application for fludrocortisone
... A survey of Paediatric Endocrinologists from the Asia Pacific region suggested unaffordably available medication plays a major role in determining survival17. Examples of low income countries where prevalence figures are known include¹⁵: no children known to be living with CAH in Timor (populati ...
... A survey of Paediatric Endocrinologists from the Asia Pacific region suggested unaffordably available medication plays a major role in determining survival17. Examples of low income countries where prevalence figures are known include¹⁵: no children known to be living with CAH in Timor (populati ...
Difficult/therapy-resistant asthma ERS TASK FORCE
... of these associations, it is not known whether these are direct or indirect effects, but they do provide areas where therapeutic possibilities can be investigated. At the more mechanistic and research level, potential risk factors that may contribute to difficult/therapy-resistant asthma may involve ...
... of these associations, it is not known whether these are direct or indirect effects, but they do provide areas where therapeutic possibilities can be investigated. At the more mechanistic and research level, potential risk factors that may contribute to difficult/therapy-resistant asthma may involve ...
Myeloma Matters vol 8 issue 3
... in the bone marrow microenvironment and suppresses the myeloma-induced overproduction of bone-destructing cells. Valproic acid has also been shown to work well in synergy with other myeloma drugs, including thalidomide, melphalan and dexamethasone. The results are encouraging and warrant further res ...
... in the bone marrow microenvironment and suppresses the myeloma-induced overproduction of bone-destructing cells. Valproic acid has also been shown to work well in synergy with other myeloma drugs, including thalidomide, melphalan and dexamethasone. The results are encouraging and warrant further res ...
LASER RESURFACING OF THE SKIN FOR THE IMPROVEMENT OF FACIAL ACNE SCARRING
... population experience acne vulgaris during their lifetime, usually during adolescence or early twenties, of varying severity and duration. The data on prevalence of scarring are limited, but it is likely that around 1% of the population will have scarring after the conclusion of their active acne. I ...
... population experience acne vulgaris during their lifetime, usually during adolescence or early twenties, of varying severity and duration. The data on prevalence of scarring are limited, but it is likely that around 1% of the population will have scarring after the conclusion of their active acne. I ...
Epinephrine for First-aid Management of Anaphylaxis
... that is rapid in onset and may cause death. Epinephrine (adrenaline) can be life-saving when administered as rapidly as possible once anaphylaxis is recognized. This clinical report from the American Academy of Pediatrics is an update of the 2007 clinical report on this topic. It provides informatio ...
... that is rapid in onset and may cause death. Epinephrine (adrenaline) can be life-saving when administered as rapidly as possible once anaphylaxis is recognized. This clinical report from the American Academy of Pediatrics is an update of the 2007 clinical report on this topic. It provides informatio ...
Understanding Ankylosing Spondylitis
... SIM0197_Understanding_AnkylosingSpondylitis_V3FA.indd 10 ...
... SIM0197_Understanding_AnkylosingSpondylitis_V3FA.indd 10 ...
Preview the material
... and mood issues. Researchers believe that fibromyalgia amplifies painful sensations by affecting the way the brain processes pain signals.1 ...
... and mood issues. Researchers believe that fibromyalgia amplifies painful sensations by affecting the way the brain processes pain signals.1 ...
needle information for flexible and rigid cystoscopes
... weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening, and there have been reports of death. The risk of symptoms ...
... weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening, and there have been reports of death. The risk of symptoms ...
Spasticity and multiple sclerosis
... Strength training is another physiotherapy intervention often used clinically for the management of spasticity. It was previously thought that strength training might worsen muscle spasticity, but evidence has not shown this to be the case.28 Strength training is now a commonly accepted intervention ...
... Strength training is another physiotherapy intervention often used clinically for the management of spasticity. It was previously thought that strength training might worsen muscle spasticity, but evidence has not shown this to be the case.28 Strength training is now a commonly accepted intervention ...
ABBREVIATIONS
... Chronic venous insufficiency (CVI) is an important clinical condition with substantial epidemiological implications and socio-economic repercussions. In the western world the consequences of its high prevalence, the costs of diagnosis and therapy, the significant loss of working hours and the reperc ...
... Chronic venous insufficiency (CVI) is an important clinical condition with substantial epidemiological implications and socio-economic repercussions. In the western world the consequences of its high prevalence, the costs of diagnosis and therapy, the significant loss of working hours and the reperc ...
Levaquin Prescribing Information
... Levofloxacin has been shown to be active against Bacillus anthracis both in vitro and by use of plasma levels as a surrogate marker in a rhesus monkey model for anthrax (post-exposure). (See INDICATIONS AND USAGE and ADDITIONAL INFORMATION - INHALATIONAL ANTHRAX). The following in vitro data are ava ...
... Levofloxacin has been shown to be active against Bacillus anthracis both in vitro and by use of plasma levels as a surrogate marker in a rhesus monkey model for anthrax (post-exposure). (See INDICATIONS AND USAGE and ADDITIONAL INFORMATION - INHALATIONAL ANTHRAX). The following in vitro data are ava ...
draft european guidelines on the management of syphilis
... and treatment at the same visit at field level or peripheral clinics remote from laboratories. Currently, where laboratory diagnostics is available for syphilis in Europe syphilis POC tests are not recommended for use. Primary screening test(s)3,14,35-37,45,46 A TT [TPHA, MHA-TP, TPPA or EIA/CIA]. ...
... and treatment at the same visit at field level or peripheral clinics remote from laboratories. Currently, where laboratory diagnostics is available for syphilis in Europe syphilis POC tests are not recommended for use. Primary screening test(s)3,14,35-37,45,46 A TT [TPHA, MHA-TP, TPPA or EIA/CIA]. ...
BTS/SIGN Asthma Guideline Quick Reference Guide 2014
... treatment, time on current dose, the beneficial effect achieved, and the patient’s preference should all be taken into account. yy Patients should be maintained at the lowest possible dose of inhaled corticosteroid. Reduction in inhaled corticosteroid dose should be slow as patients deteriora ...
... treatment, time on current dose, the beneficial effect achieved, and the patient’s preference should all be taken into account. yy Patients should be maintained at the lowest possible dose of inhaled corticosteroid. Reduction in inhaled corticosteroid dose should be slow as patients deteriora ...
Extract from the Clinical Evaluation Report for Empagliflozin
... secretion. Diabetes is also associated with microvascular complications and elevated cardiovascular risk. The estimated worldwide prevalence of diabetes is 366 million with an increase of 50 % expected within the next 20 years. The majority of these patients will be expected to have T2DM. The curren ...
... secretion. Diabetes is also associated with microvascular complications and elevated cardiovascular risk. The estimated worldwide prevalence of diabetes is 366 million with an increase of 50 % expected within the next 20 years. The majority of these patients will be expected to have T2DM. The curren ...
Executive Summary
... 2.7.1. In patients who have a lupus inhibitor, who have no additional risk factors, and no lack of response to therapy, we recommend a therapeutic target INR of 2.5 (INR range, 2.0 to 3.0) [Grade 1A]. In patients who have recurrent thromboembolic events with a therapeutic INR or other additional ris ...
... 2.7.1. In patients who have a lupus inhibitor, who have no additional risk factors, and no lack of response to therapy, we recommend a therapeutic target INR of 2.5 (INR range, 2.0 to 3.0) [Grade 1A]. In patients who have recurrent thromboembolic events with a therapeutic INR or other additional ris ...
Corneal Crosslinking with Riboflavin and Ultraviolet A. Part II
... In contrast, certain conditions or habits of patients cause natural CXL processes in the tissues of the human body, eg, diabetes mellitus and smoking. For these patients, clinicians do not expect rapid progression of keratoconus, or progression at all; thus, they do not need close followup. The prot ...
... In contrast, certain conditions or habits of patients cause natural CXL processes in the tissues of the human body, eg, diabetes mellitus and smoking. For these patients, clinicians do not expect rapid progression of keratoconus, or progression at all; thus, they do not need close followup. The prot ...
Product Monograph - Ask Novartis Pharma
... known or suspected auditory or vestibular dysfunction. In these patients and those who are at increased risk for auditory dysfunction, it may be necessary to consider audiological assessment before initiating TOBI PODHALER therapy. Ototoxicity, manifested as both auditory toxicity (hearing loss, tin ...
... known or suspected auditory or vestibular dysfunction. In these patients and those who are at increased risk for auditory dysfunction, it may be necessary to consider audiological assessment before initiating TOBI PODHALER therapy. Ototoxicity, manifested as both auditory toxicity (hearing loss, tin ...
VA National Formulary VISN 20 Formulary by Class Formulary by Generic Name
... excluding patients with moderate to severe renal insufficiency from injectable naltrexone therapy. Prior to adding diluent to the vial of powdered drug, bring the drug to room temperature (about 45 minutes). The injection should be administered by a health care provider. Do not administer intravenou ...
... excluding patients with moderate to severe renal insufficiency from injectable naltrexone therapy. Prior to adding diluent to the vial of powdered drug, bring the drug to room temperature (about 45 minutes). The injection should be administered by a health care provider. Do not administer intravenou ...
Article PDF
... severity of disease. Epithelial forms are generally treated with oral and/or topical antiviral therapy. Until recently, five topical ophthalmic antiviral drugs have been available in the United States and Europe: idoxuridine (IDU), iododesoxycytidine, vidarabine, trifluridine 1% (Viroptic), and acy ...
... severity of disease. Epithelial forms are generally treated with oral and/or topical antiviral therapy. Until recently, five topical ophthalmic antiviral drugs have been available in the United States and Europe: idoxuridine (IDU), iododesoxycytidine, vidarabine, trifluridine 1% (Viroptic), and acy ...
BOZZA ERICKSON - Associazione di Psicoterapia Cognitiva
... has the moral right to make a decision about everything or that does not respect the limits of social position or function (Sunstein, 2005). Julie and Mark are brother and sister. They are travelling together in France on summer vacation from college. One night they are staying alone in a cabin near ...
... has the moral right to make a decision about everything or that does not respect the limits of social position or function (Sunstein, 2005). Julie and Mark are brother and sister. They are travelling together in France on summer vacation from college. One night they are staying alone in a cabin near ...
Updated International Consensus Guidelines on the
... stable for 14 days at 4-C in both plasma and whole blood (35), which may be important when specimens are shipped. There is poor interinstitutional correlation of QNAT results partly due to the historical lack of an international reference standard and variation in assay design (36). This has prevent ...
... stable for 14 days at 4-C in both plasma and whole blood (35), which may be important when specimens are shipped. There is poor interinstitutional correlation of QNAT results partly due to the historical lack of an international reference standard and variation in assay design (36). This has prevent ...
Diagnosis and management of glycogen storage disease type I: a
... cloned in 1993 by Lei et al.4 The group identified mutations causing GSD type Ia (GSD Ia) and generated a G6Pase-deficient mouse model in 1996.5 G6PC spans ~ 12.5 kb and consists of five coding exons. The human G6PT gene, SLC37A4 (OMIM# 602671), which causes GSD Ib, was cloned and found to be locate ...
... cloned in 1993 by Lei et al.4 The group identified mutations causing GSD type Ia (GSD Ia) and generated a G6Pase-deficient mouse model in 1996.5 G6PC spans ~ 12.5 kb and consists of five coding exons. The human G6PT gene, SLC37A4 (OMIM# 602671), which causes GSD Ib, was cloned and found to be locate ...
Management of multiple sclerosis
Several therapies for multiple sclerosis (MS) exist, although there is no known cure. Multiple sclerosis is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS).The most common initial course of the disease is the relapsing-remitting subtype, which is characterized by unpredictable attacks (relapses) followed by periods of relative remission with no new signs of disease activity. After some years, many of the people who have this subtype begin to experience neurologic decline without acute relapses. When this happens it is called secondary progressive multiple sclerosis. Other, less common, courses of the disease are the primary progressive (decline from the beginning without attacks) and the progressive-relapsing (steady neurologic decline and superimposed attacks). Different therapies are used for patients experiencing acute attacks, for patients who have the relapsing-remitting subtype, for patients who have the progressive subtypes, for patients without a diagnosis of MS who have a demyelinating event, and for managing the various consequences of MS.The primary aims of therapy are returning function after an attack, preventing new attacks, and preventing disability. As with any medical treatment, medications used in the management of MS may have several adverse effects, and many possible therapies are still under investigation. At the same time different alternative treatments are pursued by many patients, despite the paucity of supporting, comparable, replicated scientific study.This article focuses on therapies for standard MS; borderline forms of MS have particular treatments that are excluded.